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cucurbit[7, 8 and 10]uril: and a dinuclear
ruthenium antimicrobial complex
encapsulated in cucurbit[10]uril†
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Marshall Feterl,c,d Jeffrey M. Warner,c,d F. Richard Keene, *d,e J. Grant Collins*a
and Anthony I. Day *a
The relatively non-toxic family of cucurbit[n]uril, Q[n], have shown considerable potential in vitro as drug
delivery agents, with only a few examples of pharmacokinetic (PK) studies for drug⊂Q[n]. Drug-free Q[n]
PK studies are the next step in determining the pharmacological applicability in their drug delivery poten-
tial. The results for the first PK and bio-distribution of drug-free 14C-Q[7] are described for administration
via intravenous (i.v.) and intraperitoneal (i.p.) dosing. A study of oral administration of drug-free 14C-Q[8]
has also been undertaken to determine the time course for the gastrointestinal tract (GIT), absorption and
subsequent bio-distribution. Q[10], a potential drug carrier for larger drugs, was evaluated for its effect on
the PK profile of a dinuclear ruthenium complex (Rubb12), a potential antimicrobial agent. The Rubb12⊂Q
[10] complex and free Rubb12 were administered by i.v. to determine differences in Rubb12 plasma con-
centrations and organ accumulation. Interestingly, the PK profiles and bio-distribution observed for Q[7]
showed similarities to those of Rubb12⊂Q[10]. Drug-free Q[7] has a relatively fast plasma clearance and a
generally low organ accumulation except for the kidneys. Drug-free Q[8] showed a low absorption from
the GIT into the blood stream but the small percentage absorbed reflected the organ accumulation of
Q[7]. These results provide a better understanding of the probable PK profile and bio-distribution for a
drug⊂Q[n] through the influence of the drug delivery vehicle and the positive clearance of drug-free Q[n]
via the kidneys supports its potential value in future drug delivery applications.
Introduction
The family of macrocyclic host molecules known as cucurbit[n]
uril (Q[n]); (see Fig. 1) has recently attracted considerable
attention through the realisation of a wide-range of potential
applications – including catalysis, the modification of electro-
chemical properties, the enhancement of some analytical pro-
cesses, the synthesis of nano-materials and supramolecular
polymers, for drug delivery and the modification of various
biological processes.1–16
The Q[n] are available in a range of cavity sizes prescribed
by the number of glycoluril moieties for a particular member
(n = 5–8 and 10).1–3 Other non-classical Q[n] members are also
now available, including Q[13–15], which have limited cavities
as a consequence of their twisted structures, in the form of
Möbius strips.17,18 The three Q[n] members that are of prime
interest in the area of drug delivery are Q[7, 8 and 10], which
have cavities large enough to accommodate drug molecules or
parts of a drug molecule with cross-sections within the portal
size ranges of 5.4–10.6 Å.4–11,19 The hydrophobic regions of
a drug are encapsulated within the hydrophobic cavity and
electropositive groups can further stabilise encapsulation by
electrostatic interactions with the carbonyl-rimmed portals. As
encapsulation in Q[n] can increase the aqueous solubility of a
drug, or reduce its toxicity or its degradation into non-active
metabolites, Q[n] have been proposed as delivery vehicles for a
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number of therapeutic drugs.4–11,19–21 The drug delivery poten-
tial has been demonstrated experimentally in vitro, and in a
few cases in vivo.6,12,22,23 These are important as first steps in a
pharmacological evaluation but the effect of the Q[n]-encapsu-
lation on the pharmacokinetic (PK) profile (plasma concen-
tration as a function of time and organ accumulation) of the
drug in vivo is the next important determinant of the clinical
potential of Q[n] as a drug delivery vehicle.24–27 The Q[n]
vehicle itself has already been shown to be relatively non-
toxic.28–31 To date there are few studies of the PK effect of
encapsulated drugs in Q[n] and no studies on the PK of free Q
[n]. The few examples of PK effects with drug⊂Q[n] include
those by Ma et al. (oral administration)32 and Plumb et al.
(intraperitoneal administration)33 of drugs encapsulated in
Q[7] and have demonstrated improvements in plasma drug
concentrations. A third example by Nguyen et al. (oral adminis-
tration) of a drug/Q[6] nanoparticle also showed improved
plasma drug concentrations.34 However, it is not clear in these
examples, whether it was the free drug after it was released
from the host that diffuses into the blood stream in a sus-
tained manner, or whether the drug encapsulated in Q[7] or
Q[6] was carried into the plasma. It was anticipated that the
study described herein, would help to answer this question
through the PK profiling of free Q[7 and 8].
The increasing importance of Q[n] demonstrated by in vivo
trials raises the significance of PK studies of free Q[n],
especially for n = 7 and 8 as these cavity sizes have recently
seen increasing potential as drug delivery hosts. In this
context we present our results on the PK profiling of drug-free
14C-labelled Q[7] and Q[8] with a focus on plasma clearance
and organ accumulation. In addition, to determining the fate
of Q[7 and 8] we also report a comparative PK profile of a
relatively new potential antimicrobial agent encapsulated in
Q[10], the largest available Q[n] cavity.19 This antimicrobial
agent is the inert dinuclear ruthenium(II) complex,
[{Ru(phen)2}2(μ-bb12)]4+ {phen = 1,10-phenanthroline; bb12 =
1,12-bis[4(4′-methyl-2,2′-bipyridyl)]dodecane} (Rubb12 – see
Fig. 1, n = 12). The association complexes Rubbn⊂Q[10] have
Ka > 10
9 M−1,32 and are therefore ideal candidates to evaluate
the PK of Q[10] through the ready detection of ruthenium in
plasma and organ samples by ICP-MS quantification.
The PK profiling of Rubb12⊂Q[10] compared to free Rubb12
provided data on the PK changes asserted upon the encapsu-
lated drug and served to demonstrate parallels to the PK find-
ings of a drug⊂Q[n] relative to free Q[7] and Q[8].
Results and discussion
Drug-free 14C-labelled Q[7] and Q[8]
The few examples of published PK studies of Q[n] carrying a
drug involved a determination of the fate of the drug but not
the function (delivery potential and drug retention) or fate of
the drug carrier. A delivered drug will inevitably leave an
empty Q[n], which is a phenomenon that also needs to be
understood in terms of PK.
Drug-free Q[7] has the highest intrinsic aqueous solubility
of any of the classical Q[n] family (here “classical” refers to the
original Q[n] without substituents) and drug-free Q[8] has an
intrinsic solubility of <0.1 mM,36 while the least soluble was
drug-free Q[10] (∼25 μM).37 Drug-free Q[7] in clinical saline is
soluble to ∼35 mM, which makes this Q suitable for intra-
venous (i.v.) or intraperitoneal administration (i.p.) and PK pro-
filing while carrying a 14C-label. However, drug-free Q[8] with
its lower solubility was considered only suitable for an oral PK
study. The high stability of the Q[n], also supports its potential
applicability to an oral route for drug delivery.32,34 Q[8] and
Q[10] are only very slightly increased in solubility in saline,
although drug⊂Q[8 or 10] often have considerably higher
aqueous solubility compared to the free host, with observed
increases up to 100-fold for both.35,38
The radiolabelled 14C-Q[7 and 8] were prepared by the acid-
catalysed reaction of 14C-paraformaldehyde with glycoluril
under previously established unlabelled conditions.39
Purification was achieved by a combination of dissolution
and chromatography on cation exchange resin and each Q[n]
verified by 1H NMR.
The 14C-Q[7] was assessed for its plasma clearance pro-
perties and organ uptake in Balb/c mice after i.p. adminis-
tration, and in Sprague Dawley rats after i.v. administration.
The i.p. plasma clearance in mice (Fig. 2a) appears to fit a
2-phase (2-compartment model) exponential decay curve,
giving clearances of t1/2α = 17.0 min and t1/2β = 270.7 min
(half-lives for the two phases). Similarly i.v. administration in
Sprague Dawley rats also fitted a multiphasic clearance model,
where a t1/2β = 12.8 h, calculated from the linear 6–48 h post-
dose interval (see ESI, plasma clearance Table S1, Fig. S1 and
urine excretion Table S2†). It should be noted that the percen-
tage of the injected i.p. dose was <30%, at maximum plasma
concentration, and decreased relatively quickly.
In addition to plasma clearance, the bio-distribution
of 14C-Q[7] in mice following i.p. administration was also
Fig. 1 The structure of cucurbit[n]uril (left-hand side) and Rubbn (right-hand side).
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2017 Org. Biomol. Chem., 2017, 15, 4172–4179 | 4173
Pu
bl
ish
ed
 o
n 
20
 A
pr
il 
20
17
. D
ow
nl
oa
de
d 
by
 JA
M
ES
 C
O
O
K
 U
N
IV
ER
SI
TY
 o
n 
25
/0
6/
20
17
 2
3:
04
:0
4.
 
View Article Online
examined. Maximum organ accumulation of the 14C-Q[7] was
detected 10 min post-administration, in the spleen, liver and
brain, while the kidneys saw two activity phases at ∼20 and
∼180 min (Fig. 2b). The large amount of activity detected in
the kidneys (as opposed to the liver) suggests that Q[7] is
renally excreted unchanged, possibly through glomerular fil-
tration (in a fashion similar to β-cyclodextrin and hydroxy-
propyl-β-cyclodextrin).40 Similarly, i.v. administration of 14C-Q[7]
in rats and urine sampling, at intervals within the periods 0–4,
4–8, 8–24 and 24–48 h, showed that approximately 50% of the
excretion of 14C-Q[7] occurred within the first 4 h. The total
14C-Q[7] excreted over 48 h was 71.6% ± 16.5 of the total
administered.
Low levels of 14C-Q[7] were found accumulated in the
spleen and liver (<4%, 10 min post-administration) in com-
parison to the plasma and kidneys (18.2% and 13.7% respect-
ively, 10 min post-administration). The brain accumulated the
least activity (<0.1% ± 0.06, over the entire duration of the
study) suggesting that the 14C-Q[7] does not cross the blood
brain barrier.
Q[n] is potentially applicable for oral drug delivery in
order to protect the drug from the harsh conditions of the
Fig. 2 Bio-distribution of 14C-Q[7] in mice after i.p. administration. Percent of injected dose in plasma determined from t = 0–1440 min with the
insert highlighting the period from 10 min, x-axis log10 and y-axis as percentage of injected dose corrected for the entire plasma volume (a); organ
distribution (liver, kidneys, spleen and brain) t = 10–1440 min (b).
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gastrointestinal tract (GIT) and/or provide a mechanism for
controlled adsorption into the blood stream. In this context we
undertook a preliminary PK study of orally administered drug-
free 14C-Q[8]. A single bolus of a mix of labelled and unlabelled
Q[8] was administered to Sprague Dawley rats and the bio-
distribution established. Three time points of 2, 6 and 24 h were
measured for the stomach, small and large intestines, liver,
kidneys spleen, brain and bladder. Activity in the plasma was
measured at 11 time points up to 48 h. The plasma activity vs.
time profile showed limited absorption with a maximum con-
centration (∼0.001% of the dose), obtained at ∼2 h, followed
by an elimination phase (t1/2β = 20 h) (Fig. 3). However, the
total activity detected in the plasma was very low, consistent
with the low urine recovery of 3.6% (of the total dose adminis-
tered). Hence organ distribution was also low but proportion-
ally similar to the results found in Fig. 2.
In contrast, a relatively high recovery of activity was
measured from excreted faeces, 44.7% ± 20.4 of the total dose,
with the largest proportion occurring in the 24–48 h period.
The time course of activity for the passage through the GIT
showed a peak at 2 h for stomach and the small intestine, fol-
lowed by a peak at 6 h for the large intestine (see ESI Fig. S3†).
The low plasma activity and relatively high activity observed
in the faeces and the GIT following oral dosing are consistent
with a relatively poor absorption via this route. While drug free
Q[8] may have low absorption from the GIT this does not
exclude the value of the drug delivery vehicle from providing
protection to the drug prior to release and absorption nor does
it eliminate the possibility that a drug⊂Q[7 or 8] may have a
different absorption profile, dependent upon the drug being
carried.
PK profile of a Rubb12⊂Q[10]
Rubb12 (Fig. 1) as a potential antimicrobial agent is highly
active against both Gram-positive and Gram-negative bacteria
with retention of activity against drug-resistant strains, and it
is non-toxic against healthy eukaryotic cells at concentrations
well above its minimum inhibitory concentration (MIC).41 As
we have previously demonstrated Rubb12 can form a high
affinity, stable, water soluble complex with Q[10], and as such
is suitable to evaluate the PK of Rubb12⊂Q[10] and to compare
this with the PK of the ruthenium complex.19
The maximum single dose tolerance (MTD) for free Rubb12
and Rubb12⊂Q[10] was established in mice following i.v.
administration. It was found that encapsulation resulted in a
two-fold decrease in toxicity for Rubb12 (free – 1 mg kg
−1,
encapsulated – 2 mg kg−1). Using these dose limits, free
Rubb12 (1 mg kg
−1) was administered to mice by i.v. to estab-
lish the serum concentration profiles over a 12 h period post
injection. A comparative group of mice were also administered
with Rubb12⊂Q[10] (equal quantity of Rubb12) and serum con-
centrations of Rubb12 were quantified using Inductively
Coupled Plasma Mass Spectrum (ICP-MS) determination of
the Ru concentrations. The results of the 12 h sampling of
serum concentrations are shown in Fig. 4. After the initial
equally rapid plasma clearance for both free and Q[10] bound
Rubb12, within the first 15 min of the exponential decay curve,
there is a second clearance phase, which demonstrates a slightly
slower clearance for Rubb12⊂Q[10], t1/2β ∼150 min (Fig. 4).
Of greater significance was the bio-distribution of the free
Rubb12 compared to Rubb12⊂Q[10] in a range of organs, 6 h
after the ruthenium complex had been administered by i.v.
(Fig. 5). The primary site of accumulation for free Rubb12 was
the liver, with the kidneys, spleen, heart and lungs also exhi-
biting measurable quantities of ruthenium (∼35% of injected
dose). Interestingly, while free Rubb12 accumulated predomi-
nantly in the liver, when administered as Rubb12⊂Q[10] it was
found to be distributed in comparable amounts in both the
liver and kidneys. A substantial reduction (∼2-times less) in
accumulated complex in the liver was reflected by an increase
in the kidneys (∼4-fold). The other organs – spleen, heart
lungs and brain – all showed lower levels of accumulated
Fig. 3 Plasma concentrations of 14C-Q[8] up to 48 h, following oral
administration. Activity measured as disintegrations per minute (DPM)
and maximum activity is ∼0.001% of the dose.
Fig. 4 The comparison of the serum level of free Rubb12 and Rubb12⊂Q
[10] (1 mg kg−1 of drug) over 12 h after i.v. administration. The inset high-
lights the second phase of elimination over the period 0.5–12 h.
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Rubb12⊂Q[10] with the most notable differences found in the
spleen and heart.
The very low accumulation in the heart as a result of encap-
sulation in Q[10] may have future significance in the case of
drugs that have deleterious effects on heart tissue, as this
finding may point to a method for limiting such negative
effects of drugs delivered without encapsulation in Q[n].
Given the significant accumulation in the liver and the
kidneys of Rubb12, both free and encapsulated, a longer time
course of up to 1 week was evaluated following a single i.v.
injection. The results are shown in Fig. 6 reflecting a large per-
centage of the injected dose (∼70%). The accumulation of
ruthenium in the liver (Fig. 6a) reached a maximum level at
48 h for Rubb12⊂Q[10] from which point the accumulated
amount remained relatively constant up to 1 week. For free
Rubb12 it continues to accumulate from 6 h onwards, with
levels doubling after 1 week.
Compared to the accumulation in the liver, the quantity of
ruthenium found in the kidneys when delivered as the
Rubb12⊂Q[10] complex was maximal at 6 h and then steadily
declined to half this level by 72 h up to 1 week, indicating a
constant elimination (Fig. 6b). For the mice administered with
free Rubb12, accumulation of ruthenium in the kidneys slowly
increased over time to a level similar to that of Rubb12⊂Q[10]
after 1 week following dosing.
These results demonstrate a higher accumulation and
faster clearance of Rubb12 through the kidneys when adminis-
tered as the Rubb12⊂Q[10] complex and a significant reduction
in liver accumulation compared to administration of free
Rubb12. For an antimicrobial drug, a sufficient resident time
within the body is desirable to complete its function but it is
also important that it can be cleared from the body after
serving its purpose. The positive clearance for Rubb12⊂Q[10]
from the body as shown in Fig. 6, demonstrates a desirable
attribute imparted by Q[10] in its role as a potential drug deliv-
ery vehicle.
Conclusions
This study represents the first PK profile of the promising
class of drug delivery vehicles Q[7 and 8] in the absence of a
drug. In addition, we report the PK profiling of Rubb12⊂Q[10]
as a promising antimicrobial agent with improved PK when
Rubb12 is encapsulated in Q[10].
The acute toxicity study demonstrated that the MTD of
Rubb12 can be doubled when encapsulated as Rubb12⊂Q[10],
increasing the dose size from 1 to 2 mg kg−1. This study pro-
vides the first data on the organ accumulation for a Rubbn
complex.
The results with the 14C-Q[7] provide strong evidence that
the significant increase in kidney accumulation is due to the
renal excretion of Q[n], rather than a specific effect of a
drug⊂Q[n] complex. Consequently, it can be assumed that any
drug administered as drug⊂Q[n] will show significant levels of
accumulation in the kidneys driven largely by the Q[n] and less
by the drug that it contains. However, the level of accumu-
lation in other organs is likely to decrease also driven by the
host Q[n]. The results of this study indicate that free Q[7] is
relatively rapidly eliminated from the plasma when adminis-
tered by either i.p. or i.v. routes, and from the study with
Fig. 5 Tissue accumulation of Rubb12 after 6 h of a single dose at
1 mg kg−1 by i.v. injection of free Rubb12 and Rubb12⊂Q[10] in mice.
Fig. 6 The accumulation of Rubb12 in the liver (a) and the kidneys (b) 6,
48, 72 h and 1 week after a single 1 mg kg−1 dose of free or Rubb12⊂Q
[10] by i.v. injection.
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Rubb12, encapsulated drugs will be eliminated from the
plasma at a comparable rate to the free Q[n]. Encapsulation in
Q[n] will affect the rate a drug enters the plasma after adminis-
tration by non-intravenous routes. However, and importantly,
encapsulation in Q[n] will modify the level of drug accumu-
lation in various organs. This has potentially important impli-
cations for the toxicity of the encapsulated drug.
The results from oral administration of 14C-Q[8] demon-
strated that absorption of Q from the GIT into the blood
stream is very low, and that the most likely application of
drug⊂Q[n] is for protection and increased aqueous solubility
to facilitate intestinal absorption. This suggestion is also sup-
ported by the reported improvements achieved for the drug
triamterene⊂Q[7], which showed improved bioavailability and
sustained plasma concentrations.32
Encapsulation in Q[10] with respect to plasma concen-
trations only led to a small increase in the concentration of
Rubb12, following the initial rapid concentration decrease to a
linear elimination phase at ∼30 min. After this point there was
a slightly higher concentration of Rubb12. Similarly, a reported,
i.p. administered cisplatin⊂Q[7] complex decreased the
maximum concentration in plasma, but slightly increased the
concentration after the initial rapid build up of the drug fol-
lowing i.p. administration.33
The tissue distribution study demonstrated that the main
site of accumulation for Rubb12 is the liver, with considerable
quantities also being found in the spleen and kidneys. The
concentrations of Rubb12 in the liver and kidneys were found
to continually increase over time, up to one week after
administration. This implies that the rapid clearance from
the blood stream did not lead to a rapid excretion of Rubb12
from the body, instead the complex concentrated in tissue as
shown by the organ accumulation. Interestingly, Rubb12⊂Q[10]
exhibited a considerable lowering of accumulated Rubb12
in most of the organs except for the kidneys. Significantly, the
amount of Rubb12 accumulating in the liver decreases,
approximately 2-fold when administrated as Rubb12⊂Q[10]
and as the MTD was also improved, this may suggest that the
main mechanism of toxicity of the Rubb12 complexes was liver
damage.
There are PK profile similarities between Q[7 and 8] and
even without following the fate of free Q[10] directly, the
Rubb12⊂Q[10] complex exhibited a profile comparable to free
Q[7 and 8]. Assuming that there was no significant chemical
instability due to 14C labelling,42 these results suggest that the
PK and bio-distribution will be dominated by the host for
drugs⊂Q[7,8 and 10] where drug binding is relatively high.
Experimental
All the animal experiments were carried out in accordance
with the institutional guidelines following approval from the
respective animal ethics committees (University of Queensland
Animal Ethics Committee Group 5) Project code TetraQ/059/
09/NEWSOUTH; (James Cook University Animal Ethics
Committee) App. no. A1753; (University of Wollongong Animal
Ethics Committee) App. no. AE08/14.
Animals
Mixed-sex in-bred BALB/c mice aged 9–12 weeks were obtained
from the small animal house located at the College of Public
Health, Medical and Veterinary Sciences, James Cook
University, Townsville, Australia.
Male Sprague Dawley rats 9–13 weeks were obtained from
the Australian Institute of Bioengineering and Nanotechnology
Animal House, University of Queensland.
In all studies food and water were available ad libitum
throughout the life of the animals.
Synthesis of 14C-labelled Q[7] and Q[8]
14C-labelled Q[7] and Q[8] were prepared by our general cucur-
bit[n]uril synthetic method39 on a scale where solid 14C-para-
formaldehyde (186.0 mg, 1 mCi, 37 MBq) was used in a reaction
vial with HCl 32% (400 μL). After the reaction was complete
the acid was completely removed and the dry solid residue
treated with water (16 mL) at 90 °C cooled and centrifuged.
The clear aqueous solution was separated from the solid plug.
The water was evaporated at 60 °C and the residue purified on
a short column of Dowex 50WX2 cation exchange resin,
eluting with 0.5 M HCl/50% formic acid. The appropriate frac-
tions yielded 14C-cucurbit[7]uril 120 mg. The water insoluble
material was suspended in 60% formic acid heated to 60 °C
and then cooled. The remaining suspension was centrifuged.
The solution was removed from the solid plug, which was then
washed with a small volume of 60% formic acid and the cen-
trifugation process repeated. The remaining solid was dried at
50 °C to give 14C-cucurbit[8]uril (35 mg).
All samples of radiolabelled Q were stored as solids at
−20 °C and used within a period of several months (the i.p.
experiments were conducted with samples stored for <3 weeks)
to minimise radiolytic decomposition.42
Intraperitoneal (i.p.) experiments with 14C-Q[7]in mice
The intraperitoneal (i.p.) experiments with the free Q[7] were
carried out using 14C-Q[7] with BALB/c mice. Saturated solu-
tions of 14C-Q[7] were prepared in phosphate buffer saline (pH
7.4) by sonication, then heating to 95 °C cooled and filtered
through 22 μm nylon syringe filters into sterile plastic sample
tubes. Mice were injected (i.p.) with a single bolus dose (50 μL)
of 14C-Q[7] then sacrificed at 10, 20, 30, 60, 180, 360, 720 and
1440 min after injection. The total amount of activity injected
per mouse was 4 μCi. Blood was immediately collected into
tubes containing EDTA and plasma samples taken after cen-
trifugation. Major organs were collected and weighed for
further tissue/organ analysis. Samples were accurately weighed
(between 0.1–0.5 g) and processed for liquid scintillation
counting by incubation for 24 h at 60 °C with tissue solubil-
iser. Radioactivity was measured following mixing of the
denatured homogenate sample with Packard Ultima Gold
liquid scintillation counting cocktail (approximately 10 mL).
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Intravenous (i.v.) experiments 14C-Q[7] in rats
The i.v. administration experiments with 14C-labelled Q[7]
were carried out using Sprague Dawley rats. Blood samples
were collected at 0, 2, 5, 10, 30 min, 1, 2, 4, 6, 12, 24 and 48 h
post-dose into samples tubes containing the anti-coagulant
lithium heparin. Samples were kept cold and centrifuged and
the plasma transferred to a clean, polypropylene tubes. A
50–100 µL plasma aliquot was used to determine radioactivity.
Urine samples were collected at intervals pre-dose, 0–4 h,
4–8 h, 8–24 h and 24–48 h. Urine volume was determined by
weighing. At the end of the 48 h period the collecting funnel
was washed and the activity measured added to the total.
Oral experiments 14C-Q[8] in rats
14C-Q[8] was administered as a single bolus dose (2 mL kg−1)
as a water/PEG 400 solution (5 μCi of 14C-Q[8] in 20 mg kg−1
cold Q[8]) by oral gavage. The animals were euthanased at
three post-dose time points of 2, 6 24 h. The organs (stomach,
small and large intestines, liver, kidneys, spleen whole brain
and bladder) were excised, weighed and processed.
Homogenated samples were accurately weighed (between
0.1–0.5 g) and processed for scintillation counting by incu-
bation for 24 h at 60 °C with tissue solubiliser. Radioactivity
was measured following mixing of the denatured homogenate
sample with Packard Ultima Gold liquid scintillation-counting
cocktail (approximately 10 mL).
Faeces collected during each time period were weighed and
homogenised in 4 volumes of deionised water using a mechan-
ical homogeniser. Approximately 0.1 to 1 g (accurately
weighed) of this slurry was transferred to a 20 mL glass scintil-
lation vial, 2 mL of tissue solubiliser added and the vials
capped and incubated at 60 °C for at least 24 h.
The level of radioactivity in dose formulation, plasma (50 or
100 µL), urine (100 µL), faeces (0.1 to 1 g) and washout solu-
tion (100 µL) was added to scintillation vials containing
Packard Ultima Gold liquid scintillation-counting cocktail
(2.0 mL for plasma and dose, 5.0 mL for urine and cage wash-
ings, 10 mL for faeces).
Rubb12 and Rubb12⊂Q[10] in vivo experiments
Rubb12 and Q[10] were prepared as previously described.
19
Pharmokinetic analysis of Rubb12
Preliminary acute toxicity (tolerability) studies. To enable
appropriate doses of Rubb12 to be used in the pharmaco-
kinetic studies, the maximum tolerated single dose was deter-
mined in the BALB/c mouse strain. Groups of three mice, con-
taining at least one male and one female, received intravenous
(i.v.) doses of Rubb12 or Rubb12⊂Q[10]. The doses ranged from
0.4 to 4 mg kg−1 by the i.v. route and animals were closely
monitored for 24 h. Mice exhibiting clinical adverse event
signs were euthanased via CO2 asphyxiation. The maximum
tolerated single dose was recorded as the highest dose that was
given to a group of mice where there was no mortality and no
clinical adverse event signs.
Dosing and sampling. In all the studies, three mice were
sampled at each of the time points. An untreated control
group of three mice were sacrificed and the blood sampled as
the 0 h time point. Rubb12 and Rubb12⊂Q[10] were dissolved
in sterile PBS solution at the appropriate concentrations to
obtain the desired doses relative to the Rubb12. Rubb12 solu-
tions, (approximately 200 µL) were administered to the mice at
1 mg kg−1 intravenously (i.v.), as boluses to the mice through a
26.5-gauge needle, into a tail vein. After administration, blood
was sampled at 0, 0.25, 0.5, 1, 3, 6, 12 h after dosing, and the
brain, heart, lungs, liver, kidney (left side) and spleen were col-
lected from mice 6, 48, 72 h and 1 week after a single dose.
Blood was collected from the mice by cardiac puncture
immediately after they were sacrificed and then transferred to
1.7 mL eppendorf micro-centrifuge tubes. The samples were
kept in the fridge at 4 °C until the blood was completely clotted
and then the serum was separated by centrifugation at 3000g
for 5 min. Tissues were washed with sterile PBS and weighed.
Serum and tissue samples were stored at −20 °C until analysis.
Sample preparation and digestion. Blood serum samples
were thawed and diluted 20-fold in Milli-Q water for ICP-MS
analysis. Organ samples were digested using a microwave oven
(Milestone Starter D). Fresh samples were placed in a digestion
vessel, SupraPure double-distilled 65% HNO3 (3 mL), AR Grade
H2O2 (1 mL) and Milli-Q water (4 mL) added and the mixture
was left in the fume hood for 2 h to digest the organ. The
vessel was then loaded into the microwave oven, and heated to
180 °C for 10 min. After cooling, the digested samples were
quantitatively transferred into a 100 mL volumetric flask and
diluted to the mark using Milli-Q water. These solutions were
diluted 2-fold before ICP-MS analysis.
Ruthenium concentration determination by ICP-MS. Sample
analysis was carried out using a Bruker 820-MS Inductively
Coupled Plasma Mass Spectrometer. A ruthenium standard
(1000 mg L−1 ruthenium in 2% HCl) was used for calibration.
The concentrations of 99Ru and 101Ru were measured and the
101Ru isotope was used for quantification. A 20 ppb solution of
the ruthenium standard was used to calibrate the instrument,
indium was used as an internal standard to correct for the
instrument drift and matrix effects. A 5 ppb independent
ruthenium standard was used as the quality control sample.
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